glp 1 receptor agonist diabetes Science Behind GIP and Glucagon Agonists for Obesity Research | News & Announcements Targeting GLP-1, GIP & GCG

But researchers who stop there are missing the bigger picture, and it is a much bigger picture than most people realize

Most state Medicaid programs dont cover the new class of weight loss drugs for obesity, but that could soon change

general adult population exceeds the recommendations for saturated fat (38)

The following sources give you the unfiltered picture - clinical evidence, regulatory context, and safety data straight from the organizations that publish it: FDA.gov - official FDA communications on compounded semaglutide, tirzepatide, and the 503B Bulks List proposal (April 30, 2026)

Prices for Wegovy range from 119 to 299